NasdaqGS:ABCLLife Sciences
What AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders
AbCellera Biologics Inc. recently appointed Lynn Seely, M.D., president and CEO of Lyell Immunopharma and former Myovant Sciences chief executive, to its Board of Directors as an independent director, adding deep experience in oncology and commercializing complex therapies.
Her background leading drug programs from first-in-human trials through approvals and major acquisitions may influence how AbCellera shapes its pipeline priorities and commercialization plans.
We’ll now examine how adding...